Innovative EEG Headset Recognized for Potential to Improve Patients’ Lives, and Reduce Healthcare Costs
On Jan. 25, 2016, Nielsen Consumer Neuroscience participated in a technology exposition held by the government of Saxony-Anhalt in Germany. At the summit, the Nielsen team presented the benefits of the Fourier One (F1) dry contact wireless electroencephalogram (EEG) headset to German Chancellor Angela Merkel, as part of the German government’s annual display of technologies.
The F1 headset recently won the prestigious Hugo Junkers Innovation Award in the applied science category in recognition of its successful medical trial demonstrating favorable outcomes for improving patients’ lives and lowering costs of treatment. The F1 headset has received funding from the German government for additional trials slated to begin this year.
While Nielsen Consumer Neuroscience initially developed the F1 headset for improving marketing needs, the team quickly saw how it could benefit the health industry. The F1 headset is a remarkable example of how a single product can flourish when applied in both medical and marketing settings.
For medical applications, the F1 headset is being embraced for home health monitoring—the product has shown the ability to read EEG with the same quality that a patient would find in a hospital while also reducing costs. For marketing, it introduces a new level of comfort for participants of consumer neuroscience research with lower cost and broader scale.
“Nielsen has always been a pioneer in the area of measurement. The beauty of our continuous investment in innovative technologies is that every day we are finding new ways to measure performance, impact and impressions. It’s exciting for all of us that our advances in providing better measurement in the medical arena are finding new uses and applications,” said Dr. Carl Marci, Chief Neuroscientist and Executive Vice President of Nielsen Consumer Neuroscience.
Before Nielsen presented the F1 headset to Angela Merkel, the Prime Minister of Saxony-Anhalt, Dr. Reiner Haseloff said, “There has been a fruitful cooperation between the neurological clinic and Nielsen since 2012. In a two-year study, the wireless headset showed technical measuring equivalence with standard hospital EEG equipment. This successful cooperation with the neurological clinic has encouraged Nielsen to invest further in the development of the headset, and Nielsen will start a new business in the field of medical engineering in Magdeburg, Germany, where the headsets will also be produced.”
“Saxony-Anhalt is committed to creating a business environment where innovation can flourish. We are proud that Nielsen has chosen to develop its breakthrough EEG technology right here. We hope the technology will positively change the lives of many patients and allow us to provide better care for our citizens as well,” said Dr. Carlhans Uhle, General Manager of the Investment and Marketing Corporation of Saxony-Anhalt.
One of Nielsen’s global neuroscience advisors, Dr. Hans-Joachim Heinze, initially identified a potential use for the technology within consumer neuroscience while working in the medical field.
“Our technology has come full circle and is a boon to the medical field, with potential for testing in hospitals, said Dr. Heinze. “A boomerang effect has been created, allowing technology that was repurposed from the medical field for the benefit of consumer neuroscience to be a great asset to the medical field.”
The government of Saxony- Anhalt will financially support the required field study conducted by the Otto-von Guericke University Magdeburg through subsidies within the research program autonomy in aging, and with cooperation between Nielsen, the ministry of Science and the Economy of Saxony-Anhalt.
“The F1 headset has the potential to revolutionize the patient experience and provide much needed technology for home health monitoring, as the F1 appears to be as good at reading EEG in the home. This could save costs and avoid expensive hospital monitoring of patients who are suspected of having seizures or are in need of EEG for other neurological disorders,” said Dr. Robert Knight, Professor of Neuroscience at UC Berkeley and Chief Science Advisor for Nielsen Consumer Neuroscience.
Following Nielsen’s acquisition of Innerscope Research, the combined entity is now the largest consumer neuroscience organization in the world. Nearly 20 Ph.D. and M.D. neuroscientists lead our research efforts, supported by a science advisory board comprising members from leading academic institutions around the world. The 20 scientists who work for Nielsen Consumer Neuroscience have authored more than 550 peer-reviewed articles, won more than a dozen Great Mind Awards from the Advertising Research Foundation and secured the largest intellectual property portfolio in the pervasive neurotechnology industry. According to a Sharpbrains Study, Nielsen is the No. 1 patent holder in pervasive neurotech out of over 800 organizations based on SharpBrains IP Strength Index. Today, there are more than 8,000 active patents and 5,000 pending patents in this area, contributing to a 500% growth in related patent activity in the past decade.
Nielsen Consumer Neuroscience also works with a variety of institutions and individuals to use our neuroscience capabilities for the broader good, reinvesting more than 5% of revenues to support specific causes. Whether we’re helping with epilepsy research or optimizing a non-profit campaign, we are committed to supporting organizations to effect positive social change.